Currently Viewing:
Currently Reading
What We're Reading: FDA Approvals; Sanofi Caps Price Hikes; BCBS Steps into Tenn. Marketplace
May 10, 2017 – AJMC Staff
Avelumab Gains Accelerated Approval for Urothelial Carcinoma
May 09, 2017 – AJMC Staff
What We're Reading: Drug Discounts for Uninsured; Life Expectancy; Duchenne Drug Price
May 09, 2017 – AJMC Staff
5 Reactions to the Upton Amendment That Helped the AHCA
May 05, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: May 5, 2017
May 05, 2017
What We're Reading: Voting on AHCA; High-Risk Pools; Altering Medicaid Expansion Programs
May 04, 2017 – AJMC Staff
WHO Taps Into Biosimilars for Access to Expensive Cancer Drugs in Poor Nations
May 04, 2017 – Surabhi Dangi-Garimella, PhD
House Republicans Pass Replacement for Obamacare
May 04, 2017 – Mary Caffrey
Screening Rate Disparities for Some Cancers May Have Decreased After ACA, Study Finds
May 03, 2017 – Christina Mattina

What We're Reading: FDA Approvals; Sanofi Caps Price Hikes; BCBS Steps into Tenn. Marketplace

AJMC Staff

FDA Approvals Up Sharply in 2017

Less than half of the way through 2017, the FDA has approved almost as many new treatments as it had for the entire year of 2016. According to Fortune, the slow pace of approvals in 2016 was an anomaly compared to the previous 2 years when 45 (2014) and 41 (2015) therapies were approved. However, the approvals so far in 2017 have been important with several drugs that are the first to treat certain diseases in the United States.


Sanofi Limits Drug Price Increases

More and more drug makers are beginning to self-police the industry when it comes to limiting drug price increases, and Sanofi has taken a unique and strict step. While many companies have promised to keep increases under 10%, Sanofi plans to tie drug price increases to the national health expenditures growth projection rate, reported Reuters. In 2017, that would limit price increases to 5.4%. The company has said that tying drug price increases to the inflation rate ensures the company “is not contributing to further medical inflation.”


BCBS Steps Into Empty Tennessee Marketplace

After Humana decided it was exiting all the Affordable Care Act (ACA) exchanges, 16 counties in Tennessee were at risk of having no insurer offering exchange plans next year. However, BlueCross BlueShield of Tennessee (BCBST) is stepping up to the plate and will offer plans in the Knoxville region for 2018, according to The Wall Street Journal. BCBST had exited the Knoxville market for 2017, but is interested in returning now that its financial performance in the ACA exchanges has improved.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up